Core Insights - CVS Health Corporation is a leading American healthcare company with a market cap of $104.6 billion, providing prescription medications, health services, and insurance solutions [1] - The company is set to announce its fiscal Q3 earnings for 2025 on October 29, 2025, with analysts projecting a profit of $1.36 per share, a 24.8% increase from the previous year [2] - CVS has shown strong performance, with a 42.8% gain over the past 52 weeks, significantly outperforming the S&P 500 Index and the Health Care Select Sector SPDR Fund [4] Financial Performance - Analysts expect CVS to report an EPS of $6.36 for the current year, reflecting a 17.3% increase from $5.42 in fiscal 2024, with further growth anticipated to $7.16 in fiscal 2026 [3] - CVS has consistently surpassed Wall Street's bottom-line estimates in the last four quarters [2] Recent Developments - On October 15, CVS Health shares rose 1.3% following the completion of its acquisition of select Rite Aid and Bartell Drugs assets, adding 63 stores and bringing over nine million former patients under CVS's care [5] - Wall Street analysts maintain a highly optimistic outlook on CVS stock, with a "Strong Buy" rating from 20 out of 25 analysts, and a mean price target of $85.26, indicating a 2.7% premium from current levels [6]
CVS Health’s Quarterly Earnings Preview: What You Need to Know